Therapeutic Area Expertise

Therapeutic depth in oncology clinical development, immunology, and critical care

The DF Clinical physician network works in oncology clinical development, immunology, inflammation, and critical care, as medical monitors and as senior development leads. Depth is concentrated in solid tumors and in sepsis, and it is applied to the decisions a program actually faces rather than presented as a list of indications.

Therapeutic experience changes practice. A physician who has run trials in an indication reads an eligibility question, a safety signal, or a site's enrollment problem differently from one who has not. The judgment about what is expected in a disease, on a given modality, at a given line of therapy, is the reason therapeutic matching matters.

Oncology

Solid tumor clinical development across immunotherapy, cell therapy, and targeted agents

Network experience covers solid tumors including metastatic colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer, in early phase and in randomized studies, spanning indication and population selection, protocol and eligibility design, medical monitoring during conduct, safety governance, and regulatory document development.

Modalities

Cancer immunotherapy
Allogeneic cell therapy
Oncolytic viruses
Small molecule targeted agents
Combination chemotherapy and biologic regimens
Supportive care approaches associated with oncology treatment

Cell based immunotherapy led at chief medical officer level

Programs for an allogeneic Th1 cell based immunotherapy were led at chief medical officer level with three trials recruiting concurrently: a Phase 2b single arm study in third line metastatic colorectal cancer, a randomized Phase 2/3 study in advanced hepatocellular carcinoma conducted in Thailand and Malaysia, and a Phase 1 study in healthy elderly volunteers.

Running three studies at once means eligibility conventions, safety reporting practice, and enrollment assumptions must hold together across populations and geographies, which is how an oncology drug development consultant is usually needed to work.

Current oncology medical monitoring at Sitero

Current medical monitoring at Sitero includes a second line metastatic colorectal cancer study of an oncolytic virus and an advanced non-small cell lung cancer program involving a small molecule telomere targeting agent. Both require medical review at the pace of enrolling studies: eligibility questions, adverse event assessment, laboratory and clinical data review, protocol deviation decisions, and direct resolution of investigator queries.

Supportive care in first line metastatic colorectal cancer

Clinical development of a thrombomodulin program for prevention of oxaliplatin induced peripheral neuropathy in first line metastatic colorectal cancer included serving as sponsor lead for a Type B pre-IND meeting with FDA divisions covering anesthesiology and pain medicine, neurology, and oncology. A supportive care indication sitting across three review divisions is a case where the regulatory question and the clinical question cannot be separated.

Immunology, Inflammation & Critical Care

Immunology clinical development, sepsis clinical trial design, and critical care programs

Sepsis and sepsis associated coagulopathy

Clinical development leadership for a global Phase 3 program of approximately 800 patients across 159 sites in 25 countries covered protocol design, medical monitoring, safety governance, investigator and key opinion leader networks, and enrollment acceleration for a highly enriched trial population.

Enriched critical care populations are where enrollment assumptions fail quietly, and screening a narrow phenotype in an intensive care unit is usually solved by changing what sites are asked to do rather than by adding sites. This work included serving as lead company representative in FDA interactions, including negotiation of a potential single Phase 3 approval pathway.

Hematology and immunology biologics

Programs span thrombomodulin, plasmin, alpha-1 antitrypsin, Factor VIII, and first-in-human monoclonal antibody immunotherapy, including Phase 2 development of intra arterial plasmin for acute peripheral arterial occlusion and acute ischemic stroke. Biologics in bleeding, clotting, and immune indications require safety review that reads a laboratory result against the mechanism rather than a generic reference range.

Current first-in-human work

Current work includes a first-in-human program for a monoclonal IgM antibody B cell depleting agent in sepsis, where dose decisions, eligibility interpretation, and event assessment need a physician available while the study runs.

Across Therapeutic Areas

General clinical development capability

Much of clinical development is not therapeutic area specific. Development strategy, protocol design, medical monitoring practice, safety governance, CRO oversight, site and enrollment strategy, and regulatory interaction transfer across indications, and are applied wherever the clinical question sits. The full scope of that work is described under clinical development services.

Physicians are matched to assignments based on therapeutic background and relevant program experience, not availability alone. How matching works in practice is covered under clinical trial medical monitoring and site feasibility and enrollment support. Physicians who want to be considered for matched assignments can join the network.

Common Questions

Questions about therapeutic area experience

What does an oncology clinical development consultant do?

An oncology clinical development consultant provides the physician judgment a program needs without a permanent hire: indication and population selection, protocol and eligibility design, medical monitoring during conduct, safety governance, and regulatory document development. In practice the work is deciding what a trial should ask, then holding the medical decisions while it runs.

Why does therapeutic area experience matter in medical monitoring?

A physician who has run trials in an indication reads the same information differently. An eligibility question, a laboratory shift, an adverse event pattern, or a site that is enrolling slowly carries a meaning that depends on what is normal for that disease and that modality. Therapeutic depth is what separates a medical review that catches a developing problem from one that documents it after the fact.

Which therapeutic areas does DF Clinical cover?

Core depth is oncology, particularly solid tumors, together with immunology, inflammation, and critical care including sepsis. General capability such as protocol design, safety governance, CRO oversight, and site and enrollment strategy applies across indications.

Discuss a program in one of these areas.

Describe the indication, the stage of development, and the decision in front of you, and we will tell you plainly whether the network's experience is relevant.

Schedule a Consultation david@dfclinical.com